Olema Pharmaceuticals (OLMA) News Today → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free OLMA Stock Alerts $9.84 +0.18 (+1.86%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 5:50 AM | americanbankingnews.comOlema Pharmaceuticals' (OLMA) Buy Rating Reaffirmed at HC WainwrightMay 18 at 1:47 AM | americanbankingnews.comOlema Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.50) Per Share, HC Wainwright Forecasts (NASDAQ:OLMA)May 17 at 7:10 AM | marketbeat.comQ2 2024 Earnings Estimate for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Issued By HC WainwrightOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Olema Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.50) peMay 16 at 5:32 PM | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib CombinationMay 16 at 5:32 PM | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals Amid Promising Clinical Trial Results for Breast Cancer TherapyMay 16 at 2:31 AM | markets.businessinsider.comBuy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals’ Drug Combination in Clinical StudiesMay 16 at 2:31 AM | markets.businessinsider.comPromising Combination Therapy Drives Buy Rating for Olema PharmaceuticalsMay 15, 2024 | markets.businessinsider.comPromising Clinical Trial Results Bolster Buy Rating for Olema PharmaceuticalsMay 15, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.17Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.17May 15, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday.May 15, 2024 | globenewswire.comOlema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer CongressMay 14, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Victory Capital Management Inc.Victory Capital Management Inc. boosted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 879.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 621,527 shareMay 13, 2024 | americanbankingnews.comFY2028 EPS Estimates for Olema Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:OLMA)May 13, 2024 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) PT Raised to $28.00 at HC WainwrightMay 13, 2024 | americanbankingnews.comLifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:OLMA)May 11, 2024 | americanbankingnews.comLifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:OLMA)May 11, 2024 | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by BrokeragesMay 10, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.52) Per Share (NASDAQ:OLMA)Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at Lifesci Capital issued their Q3 2024 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 8th. Lifesci Capital analyst S. Slutsky forecasts that theMay 10, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial PositionMay 9, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals: Financial Stability and Promising Drug Development Fuel Positive OutlookMay 9, 2024 | americanbankingnews.comCyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis CollaborationMay 8, 2024 | investorplace.comOLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024May 8, 2024 | globenewswire.comOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressMay 8, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 5,000 SharesMay 3, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $142,650.00 in StockMay 2, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 15,000 SharesOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 15,000 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total value of $142,650.00. Following the completion of the sale, the director now owns 811,283 shares of the company's stock, valued at $7,715,301.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferences in MayApril 21, 2024 | finance.yahoo.comOlema Pharmaceuticals, Inc. (OLMA)April 18, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%April 12, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive EdgeApril 10, 2024 | bizjournals.comHow Olema Oncology moved from layoffs to pivotal cancer drug studiesApril 8, 2024 | globenewswire.comOlema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceApril 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89April 2, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group assumed coverage on Olema Pharmaceuticals in a report on Tuesday. They issued a "buy" rating and a $24.00 price objective for the company.April 1, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 5.4% After Insider SellingOlema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.4% on Insider SellingMarch 30, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $219,400.00 in StockMarch 29, 2024 | marketbeat.comInsider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells 20,000 Shares of StockOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $10.97, for a total value of $219,400.00. Following the completion of the sale, the director now directly owns 826,283 shares of the company's stock, valued at approximately $9,064,324.51. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.March 28, 2024 | seekingalpha.comPalazestrant's Journey: Olema Pharmaceuticals' Long Oncology PathMarch 19, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6.9%Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.9%March 16, 2024 | finance.yahoo.comOLMA Jul 2024 12.500 callMarch 16, 2024 | finance.yahoo.comOLMA Apr 2024 22.500 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 25.000 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 10.000 putMarch 14, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Down 21.2% in FebruaryOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the target of a significant decline in short interest in February. As of February 29th, there was short interest totalling 4,870,000 shares, a decline of 21.2% from the February 14th total of 6,180,000 shares. Based on an average daily volume of 825,000 shares, the short-interest ratio is presently 5.9 days.March 14, 2024 | marketbeat.comFY2024 EPS Estimates for Olema Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:OLMA)Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Capital One Financial increased their FY2024 EPS estimates for Olema Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. Capital One Financial analyst N. Quibria now anticipates that the company willMarch 13, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 11.9%Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 11.9% Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. OLMA Media Mentions By Week OLMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼0.560.42▲Average Medical News Sentiment OLMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼253▲OLMA Articles Average Week Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HROW News CMPS News SIGA News ALT News CDMO News IGMS News ABUS News AVTE News STOK News YMAB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
